We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current AKBA market cap is 533.69M. The company's latest EPS is USD -0.2938 and P/E is -7.59.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 56.2M | 32.61M | 43.65M | 37.43M | 46.5M |
| Operating Income | 1.37M | -14.94M | -8.72M | -12.51M | -14.31M |
| Net Income | 614k | -17.99M | -8.58M | -20.04M | -22.8M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 295.31M | 213.58M | 292.6M | 194.62M | 160.18M |
| Operating Income | -376.44M | -265.32M | -79.12M | -46.26M | -50.47M |
| Net Income | -383.46M | -282.84M | -92.56M | -51.93M | -69.41M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 241.7M | 225.48M | 220.2M | 207.14M | 220.67M |
| Total Liabilities | 272.29M | 252.74M | 253.95M | 257.54M | 269.86M |
| Total Equity | -30.58M | -27.26M | -33.75M | -50.4M | -49.19M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 644.14M | 525.55M | 351.83M | 241.7M | 220.67M |
| Total Liabilities | 396.52M | 449.09M | 342.49M | 272.29M | 269.86M |
| Total Equity | 247.62M | 76.46M | 9.34M | -30.58M | -49.19M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -23.38M | -19.43M | -29.5M | -36.19M | -40.66M |
| Investing | N/A | N/A | -29k | -31k | -33k |
| Financing | -25.21M | 18.48M | 26.12M | 27.34M | 49.66M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -110.39M | -252.97M | -73.15M | -23.38M | -40.66M |
| Investing | -40M | 39.94M | -114k | N/A | -33k |
| Financing | 231.72M | 133.73M | 14.6M | -25.21M | 49.66M |
| Market Cap | 533.69M |
| Price to Earnings Ratio | -7.59 |
| Price to Sales Ratio | 3.29 |
| Price to Cash Ratio | 10.15 |
| Price to Book Ratio | -10.71 |
| Dividend Yield | - |
| Shares Outstanding | 236.23M |
| Average Volume (1 week) | 2.96M |
| Average Volume (1 Month) | 4.23M |
| 52 Week Change | 64.91% |
| 52 Week High | 2.89 |
| 52 Week Low | 0.80 |
| Spread (Intraday) | 0.01 (0.44%) |
| Company Name | Akebia Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.akebia.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
